COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01507454
Recruitment Status : Completed
First Posted : January 11, 2012
Last Update Posted : February 8, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.

Condition or disease Intervention/treatment
Menopause Postmenopausal Vaginal Atrophy Drug: estradiol, 25 mcg

Layout table for study information
Study Type : Observational
Actual Enrollment : 1613 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency
Study Start Date : April 2006
Actual Primary Completion Date : November 2006
Actual Study Completion Date : November 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaginitis

Group/Cohort Intervention/treatment
Local treatment Drug: estradiol, 25 mcg
Vaginal tablets for 6-12 weeks according to product labelling

Primary Outcome Measures :
  1. Percentage of subjects reporting vaginal symptoms occuring 'often' and 'frequently'
  2. Percentage of subjects reporting 'moderate' and 'severe' vaginal symptoms

Secondary Outcome Measures :
  1. Adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Women with atrophic vaginitis caused by estrogen deficiency prescribed with Vagifem® by their treating physician

Inclusion Criteria:

  • Atrophic vaginitis due to estrogen deficiency
  • Post-menopausal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01507454

Layout table for location information
Novo Nordisk Investigational Site
Mainz, Germany, 55127
Sponsors and Collaborators
Novo Nordisk A/S
Layout table for investigator information
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Additional Information:
Publications of Results:
Stute P. Urogenitale Beschwerden und Östradioltherapie: Auswirkung einer vaginalen niedrig dosierten Östradioltherapie auf die Prävalenz und Intensität von urogenitalen Beschwerden. Gynäkologische Endokrinologie 2008; 6 (1): 48-52

Layout table for additonal information
Responsible Party: Novo Nordisk A/S Identifier: NCT01507454    
Other Study ID Numbers: VAG-1935
First Posted: January 11, 2012    Key Record Dates
Last Update Posted: February 8, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrophic Vaginitis
Pathological Conditions, Anatomical
Vaginal Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs